Innocare Pharma Ltd (9969) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Innocare Pharma Ltd stock HK$10.42, price HK$11.27, that is 7.5% below the price, quality 76 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Innocare Pharma Ltd
9969 · HKStrong company, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range HK$4.06 – HK$30.65 · fair‑value band HK$7.75 – HK$12.82 · the HK$11.27 price screens above the HK$10.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Innocare Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
Show moreShow less
The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder.
It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor.
InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Stock analysis
Innocare Pharma Ltd (9969) currently trades at HK$11.27, while our model-based Fair Value estimate is HK$10.42, so the stock looks roughly fairly valued today (gap 8.1%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$22.89 per share, and 13 of the 26 models we run sit above the HK$11.27 price.
Bear case: the Asset-Based group reads lowest at HK$3.91, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: HK$7.75 (bear) to HK$12.82 (bull), the price of HK$11.27 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Innocare Pharma Ltd reported revenue of 2.3B CNY in FY2025 versus 1.0B CNY in FY2021, a compound +21.8%/yr. Reported net income was 626M CNY in FY2025.
Key figures
Market cap HK$19.9B (≈ $2.5B) Mid · P/E ratio 19.1 · P/S ratio 8.62 · EPS (TTM) HK$0.8689 · Dividend yield 0.2% · Net margin 40.6% · Return on equity 18.3% · Return on assets (EBIT) −3.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −8%, 9969 screens richer than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch 9969, get fair value alerts →
Compare Innocare Pharma Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 9969 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 9969 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 9969 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 9969 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 9969 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 9969 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 9969 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 9969 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 9969 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 9969 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Innocare Pharma Ltd (9969) overvalued or undervalued?
What is the fair value of 9969?
What is the quality score of 9969?
What is the price target for Innocare Pharma Ltd (9969)?
What is the Innocare Pharma Ltd stock forecast for 2026?
What is the revenue of Innocare Pharma Ltd (9969)?
Does Innocare Pharma Ltd pay a dividend?
How much is the dividend of Innocare Pharma Ltd (9969)?
What growth is priced into Innocare Pharma Ltd (9969)?
What discount rate (WACC) does the fair value of 9969 use?
What is a reverse DCF?
How much growth has Innocare Pharma Ltd (9969) delivered so far?
How fast is the sector of Innocare Pharma Ltd (9969) growing?
What is the free cash flow yield of Innocare Pharma Ltd (9969)?
What is the intrinsic value of Innocare Pharma Ltd (9969)?
Is Innocare Pharma Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 9969?
How much is Innocare Pharma Ltd worth?
What do the bullish and bearish scenarios say about 9969?
What is the P/E ratio of 9969?
How solid is the balance sheet of Innocare Pharma Ltd (9969)?
How far is 9969 from its 52-week high?
Which stocks are comparable to Innocare Pharma Ltd?
Is Innocare Pharma Ltd stock attractive at the current price?
How is the fair value of 9969 calculated?
Is it still worth investing in stocks now?
What is the share price of Innocare Pharma Ltd (9969)?
What should I pay attention to with Innocare Pharma Ltd right now?
Key figures of Innocare Pharma Ltd
How large is the market capitalisation of Innocare Pharma Ltd (9969)?
What is the P/S ratio of Innocare Pharma Ltd (9969)?
What are the earnings per share of Innocare Pharma Ltd (9969)?
What is the dividend yield of Innocare Pharma Ltd (9969)?
What is the net margin of Innocare Pharma Ltd (9969)?
What is the return on equity of Innocare Pharma Ltd (9969)?
What is the EBIT return on assets of Innocare Pharma Ltd (9969)?
What is the operating margin of Innocare Pharma Ltd (9969)?
How fast is revenue growing at Innocare Pharma Ltd (9969)?
How fast are earnings growing at Innocare Pharma Ltd (9969)?
How much net cash does Innocare Pharma Ltd (9969) hold?
Watch Innocare Pharma Ltd in the live analysis
One click puts Innocare Pharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.